Menu Search
Equities

Amneal Pharmaceuticals Inc

AMRX:NSQ

Amneal Pharmaceuticals Inc

Actions
  • Price (USD)8.73
  • Today's Change0.12 / 1.39%
  • Shares traded1.72m
  • 1 Year change+115.02%
  • Beta1.1411
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Amneal Pharmaceuticals Inc grew revenues 8.20% from 2.21bn to 2.39bn while net income improved from a loss of 129.99m to a smaller loss of 83.99m.
Gross margin35.04%
Net profit margin-5.13%
Operating margin6.72%
Return on assets-3.69%
Return on equity-133.96%
Return on investment-4.93%
More ▼

Cash flow in USDView more

In 2023, Amneal Pharmaceuticals Inc increased its cash reserves by 181.34%, or 63.88m. The company earned 345.58m from its operations for a Cash Flow Margin of 14.44%. In addition the company used 69.19m on investing activities and also paid 212.57m in financing cash flows.
Cash flow per share0.3573
Price/Cash flow per share29.36
Book value per share-0.1857
Tangible book value per share-4.77
More ▼

Balance sheet in USDView more

Amneal Pharmaceuticals Inc has a Debt to Total Capital ratio of 100.15%, a lower figure than the previous year's 832.76%.
Current ratio1.33
Quick ratio0.8165
Total debt/total equity--
Total debt/total capital1.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.